All News


All series


All All News

The Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, also known as EPd, for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor.

Would would happen if I turned my back to the past and faced forward? It is time to stop wishing I could go back to my pre-cancer life. It's time to face forward.

The PARP inhibitor Lynparza (olaparib) significantly improved progression-free survival (PFS) as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase 3 SOLO-1 trial presented at the 2018 ESMO Congress.

Metastatic breast cancer advocate goes to Washington DC to tell her own story and push for more research to be directed toward metastatic disease

The mammogram can be an emotional roller coaster for any person. After you have been diagnosed with breast cancer, even good results can tap into deep emotions.